Who owns Structure Therapeutics Inc. (GPCR)? Elite investor 13F holders

2 tracked elite investors reported holding Structure Therapeutics Inc as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawStructure Therapeutics IncSHARE2026-06-302026-08-14 00:00:006188151.00 USD115300.000000SharesreduceOriginal filing
Tudor InvestmentStructure Therapeutics IncSHARE2026-06-302026-08-14 00:00:002879718.00 USD53656.000000SharesreduceOriginal filing
Renaissance Technologies LLCStructure Therapeutics IncSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Ancora Advisors / Ancora HoldingsStructure Therapeutics IncSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown